Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

February 11, 2016

Study Completion Date

August 9, 2022

Conditions
Breast Cancer
Interventions
DRUG

Panitumumab

2.5 mg/kg IV on Day 1 of Week 1 over 60 minutes, followed by 2.5 mg/kg weekly Weeks 2-12.

DRUG

Nab-paclitaxel

100 mg/m2 IV over 30 min on Day 1 of Weeks 2-13 over 30 minutes.

DRUG

Carboplatin

AUC 2 IV over 30 min on Day 1 of Weeks 2-13 after completion of Abraxane through separate IV line.

DRUG

5-Fluorouracil

500 mg/m2 IV every 3 weeks, starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).

DRUG

Epirubicin

100 mg/m2 IV over 30 min every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).

DRUG

Cyclophosphamide

500 mg/m2 IV every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER